Markets
MYGN

Myriad Genetics Appoints Raj Jampa As CTO

June 02, 2026 — 09:24 am EDT

Written by RTTNews.com for RTTNews->

(RTTNews) - Myriad Genetics, Inc., (MYGN), a molecular diagnostic testing and precision medicine company, Tuesday announced that it has appointed Raj Jampa as its chief technology officer, effective June 1.

Before joining the diagnostic and precision medicine company, Jampa held senior technology leadership roles at Agilent Technologies, Exact Sciences and Genomic Health.

In pre-market activity, MYC+GN shares were trading at $4.19, down 2.10% on the Nasdaq.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

Markets
RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source->

Stocks mentioned

MYGN

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

  • •

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.